FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
U.S. Food and Drug Administration, Center for Drug Evaluation and Research
4.4from 15 ratings
- 119
- Episodes
- 15
- Ratings
- 2017
- First episode
- 42M
- YouTube views
About FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.
- Publisher
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research
- Category
- government · health & fitness · science
- Language
- en
- Explicit
- No
- First episode
- 17 May 2017
- Latest episode
- 17 Jan 2025
Latest episodes
119 episodes in the feed.
17 Jan 2025
FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients
30 Dec 2024
FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy
18 Nov 2024
FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
- YouTube views
- 41,987,183
- Score snapshot 15 Sept 2025
- Apple Podcasts (US)
- 4.4 / 5
- 15 ratings
Podcast Authority Score: 47 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
- Quality
- 38
- Social presence
- 0
- YouTube
- 93
- Engagement
- 50
Host of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show
Podcast research with Pod Engine